PRNewsWire
18 Aug 2026, 06:12 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA has accepted the Biologics License Application for imlifidase with a PDUFA action date set for December 19, 2026. — FDA approval in the US market represents the largest potential revenue catalyst for the drug's commercial growth.
+0.60Hansa Biopharma has treated its first commercial kidney transplant patient in Australia using Idefirix. — This marks the start of commercial revenue generation and real-world clinical adoption in the Australian market.
+0.30Which stocks this story touches
The company achieved a commercial milestone with the first patient treated with Idefirix in Australia.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
10h ago
